Part II: Precision Medicine in NSCLC—Implications for Molecular Testing and Treatment - a podcast by ReachMD

CME credits: 0.50

Valid until: 29-09-2021

Claim your CME credit at https://reachmd.com/programs/cme/precision-medicine-in-nsclcimplications-for-molecular-testing-and-treatment-part-ii/11726/

The discovery of predictive biomarkers has led to an improvement in overall survival (OS) and progression-free survival (PFS) in non–small cell lung cancer (NSCLC) by identifying subgroups of patients who benefit from targeted treatments. These include sensitizing epidermal growth factor receptor (EGFR) gene mutations, anaplastic lymphoma kinase (ALK) gene rearrangements, ROS proto-oncogene 1 (ROS1) gene rearrangements, B-Raf proto-oncogene (BRAF) point mutations, neurotrophic tyrosine receptor kinase (NTRK) fusions, and programmed cell death protein ligand 1 (PD-L1) expression. Many targeted therapies are currently and recently approved, with oncologic therapy decisions based on the presence of these mutations and gene rearrangements.

This activity will review the most recent clinical data and provide expert insights on biomarker testing for genetic alterations in NSCLC, and targeted therapies that are available based on the presence of identified mutations and gene rearrangements.

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD